A useful cancer drug, where cost is prohibitive:
Doctors are excited about the prospect of Avastin, a drug already widely used for colon cancer, as a crucial new treatment for breast and lung cancer, too. But doctors are cringing at the price the maker, Genentech, plans to charge for it: about $100,000 a year.
Related posts:
- Avastin
- Statistics and sensationalism
- How much do we really need mammograms?
- How does cancer screening cause harm?
- "The great majority of women in the United States should not be getting MRI scans for breast cancer screening"
- More tests is better medicine: Why the myth is hard to break
- Generics doesn’t always equal cheap
KevinMD.com on Facebook
{ 3 comments }
That doesn’t surprise me they charge me nearly $24,000 a year for my hormone replacement.
I’m not a medical oncologist.
Here’s some data.
Dosage for Avastin for metastatic colorectal cancer is 5 mg/kg q14 days “until disease progression is detected,” implyng that Avastin is given every two weeks without an end point. Probably because the patient has metastatic or stage 4 disease.
For a 165 lb. or 75 kg. patient this works out to 375 mg every 2 weeks or 9,750 mg/year.
Avastin is packaged in 100 mg vials so this 75 kg. patient would require 98 vials per year.
The quoted RETAIL price of 98 vials of Avastin at Drugstore.com is $60,638.
I would assume that Genentech would sell Avastin for a lesser wholesale price.
So by my calculations, the price of a year of Avastin for metastatic colorectal cancer should be less than half the price in this news story.
Maybe there’s a different dosage for the off-label use for breast cancer.
Please correct me if my information is incorrect.
The dose used for breast and lung cancer is double the dose used for colon cancer.
Comments on this entry are closed.